A Phase I Study of Vitargus® in Vitrectomy

Vitreo-retinal Surgery Clinical Trial

Official title:
A Phase I, Safety and Tolerability Study of Vitargus® in Vitrectomy Surgery

Status Completed

Clinical Trial Summary

A Phase I, safety and tolerability study of Vitargus® in vitrectomy surgery

Clinical Trial Description

Study Objectives:

Primary Objective

• To evaluate the safety/tolerability of a single intravitreal (IVT) dose of BFC-1401 in participants as a vitreous substitute during vitrectomy surgery.

Secondary Objective

- To assess retinal attachment and hydrogel degradation at Day 120.

- To assess best corrected visual acuity (BCVA) after vitrectomy surgery. ;

Study Design

Related Conditions & MeSH terms

Vitreo-retinal Surgery

Clinical Trial Details

NCT number	NCT04481386
Study type	Interventional
Source	BioFirst Corporation
Contact
Status	Completed
Phase	N/A
Start date	February 1, 2017
Completion date	July 2, 2018

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT04462523` - DEXTENZA for the Treatment of Postoperative Pain and Inflammation Following Vitreo-retinal Surgery	Phase 4